• Immix Receives FDA Authorization to Expand Clinical Trial americanpharmaceuticalreview
    July 25, 2019
    Immix Biopharma announced it received a letter from the FDA authorizing it to proceed with expanding its phase 1b/2a clinical trial of IMX-110 to the United States under an IND. IMX-110 is a first-in-class combination therapy designed to inhibit cancer re
PharmaSources Customer Service